prognostic performance with respect to cancer-specific survival (AUC at 10 years, 0.750; PVE, 20.9%; C-index, 0.881).
Conclusions:
The predictive performance of the revised TNM-8 in patients with MTC has not changed despite its modification from TNM-7. The proposed changes in TNM-RPA were statistically valid and may present a more reproducible system that better estimates cancer-specific survival of individual patients. (J Clin Endocrinol Metab 103: [4609] [4610] [4611] [4612] [4613] [4614] [4615] [4616] 2018) I n 2017, the American Joint Committee on Cancer/ Union for International Cancer Control (AJCC/UICC) published the revised eighth edition of the TNM cancer staging system (TNM-8). The revised staging system has substantial improvements, which included changes to age cutoffs, T categories, and staging groupings. However, despite advances in thyroid cancer staging systems, they continue to be developed on the basis of cohorts of differentiated thyroid carcinoma (DTC) (1) . In contrast to other type of thyroid cancer, medullary thyroid carcinoma (MTC) is a neuroendocrine tumor derived from C or calcitonin-producing parafollicular cells of the thyroid gland. MTC differs from DTC in terms of management and prognosis, and thus staging systems for DTC may not be applicable for MTC. However, before the revised eighth edition of the AJCC/UICC TNM staging system, the staging system for MTC was included within the DTC staging system (2, 3) . Although MTC is now a stand-alone chapter of the eighth edition, the detailed definitions of the T, N, and M categories are not different from those for DTC (4) . Furthermore, the staging groupings are identical to those of the seventh edition for DTC, with the exception that age is not used.
Controversy persists regarding how accurately the current staging system can predict prognosis for MTC. Until now, no studies have tried to quantify the predictive ability of TNM-8 for MTC. However, some reports have suggested that the previous staging systems for MTC do not stratify patients accurately with regard to prognosis (5) . Recently, Adam et al. (6) proposed alternative prognostic stage groups. Interestingly, just by regrouping the current T, N, and M categories using recursive partitioning analysis, they showed that they could better reflect the prognosis. Ultimately, additional validation studies will be required to evaluate the current staging systems for MTC.
The ability to predict which patients are at high or low risk for recurrence, disease persistence, and cancerrelated mortality is of great importance to treatment and follow-up decisions. In the current study, we evaluated the prognostic performance of TNM-8 compared with the seventh edition (TNM-7). In addition, we evaluated and attempted to validate the alternative prognostic stage groups based on recursive partitioning analysis (TNM-RPA).
Materials and Methods

Study patients
We retrospectively reviewed the medical records of patients treated at a tertiary Korean hospital between 1995 and 2015. A total of 182 patients were enrolled in this study after exclusion of 16 patients due to insufficient clinical information. The study protocol was approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2018-03-164). The committee waived patient consent in some cases because of the retrospective nature of the study.
Reclassification and survival outcomes
Demographic characteristics and laboratory results stored in an electronic medical record system were extracted automatically. Surgical reports, pathologic reports, and imaging results were reviewed by the authors. Enrolled patients were reclassified according to three staging systems: TNM-7, TNM-8, and TNM-RPA (Table 1) (6) .
Cancer-specific survival (CSS) was defined as the time from initial diagnosis to last censoring event or death caused by MTC. Survival status and cause of death were ascertained from national death certificate data from the Korean National Statistical Office. Disease-free survival (DFS) was defined as the time from initial diagnosis to the last censoring event or the first evidence of recurrence or persistence. Disease recurrence and persistence in this study referred to the presence of physical tumors of recurrent or persistent disease as confirmed by standard cytologic, histologic, and radiographic criteria.
Statistical analysis
All statistical analyses were performed by using SAS software, version 9.4 (SAS Institute Inc., Cary, NC) and R software, version 3.4.3 (R Project, Vienna, Austria). A P value , 0.05 was considered to indicate a statistically significant difference. Continuous variables are presented as the mean (SD), and categorical variables are presented as numbers (percentages). The distributions of each stage of TNM-8 and TNM-RPA were compared by using the Wilcoxon rank-sum test and Fisher I  T1N0M0  T1N0-1aM0, T2N0M0  II  T2-3N0M0  T1N1bM0, T2N1a-1bM0, T3N0M0  III  T1-3N1aM0 T3N1a-1bM0, T4N0-1bM0
exact test where appropriate. Survival was evaluated by the Kaplan-Meier method and long-rank test. CSS according to staging system was evaluated by using the Cox proportional hazard model. Area under the receiver-operating characteristic curve (AUC) was used to compare the discriminatory capacity of staging systems (7, 8) . Specifically, AUC values range from 0.5 to 1, and a larger value suggests better discriminatory capacity. The proportion of variation explained (PVE) and Harrell concordance index (C-index) were used to quantify predictive performance (9, 10) . PVE (%) values ranged from 0 to 100, and larger numbers suggest better predictability. The null value for the C-index is 0.5 with a maximum of 1.0, and a higher C-index indicates a more accurate predictive capacity.
Results
Patient demographic characteristics
A total of 182 patients (122 women and 60 men) with a mean age of 49.7 years were analyzed. Clinicopathological characteristics of the study population at baseline are shown in Table 2 . The mean primary tumor size was 2.1 cm. Among all patients, 35 (19.2%), 11 (6.0%), and 13 (7.14%) had microscopic extrathyroidal extension (ETE), gross ETE invading only strap muscles, and gross ETE invading major structures, respectively. Cervical lymph node metastases were present in 85 (52.2%) patients, and distant metastases were present in eight (4.4%) patients. The mean overall follow-up time from diagnosis to death or censoring was 95.2 months.
Reallocation of patients into cancer staging systems
After reclassification from TNM-7 to TNM-8, T categories were changed in 28 patients. Specifically, 15 patients were changed from T3 to T1, and 13 patients were changed from T3 to T2 (Table 3) . N category did not differ between TNM-7 and TNM-8. Overall, only two patients (1.1%) were downstaged in the revised TNM staging system.
Upon applying TNM-RPA, 104 (57.1%) patients were downstaged compared with TNM-7. Specifically, 17 patients were changed from stage II to I, 18 patients from III to I, four patients from III to II, 42 patients from IV to II, and 25 patients from IV to III (Table 4) . Compared with TNM-8, 106 (58.2%) patients were downstaged, with 19 patients changed from stage II to I, 18 patients from III to I, four patients from III to II, 42 patients from IV to II, and 25 patients from IV to III.
Prognostic performance of different cancer staging systems according to survival outcomes
Among the 182 patients enrolled in the study, 18 (9.9%) died of MTC at a mean (SD) of 67.4 (72.3) months after diagnosis. CSS according to TNM-7 and TNM-8 were similar, as shown in Fig. 1 (a) and 1(b). CSS curves significantly differed among the four groups in both staging systems (log-rank P = 0.007 for both). In TNM-7, the 5-year CSS rates for stage I, II, III, and IV were 100%, 100%, 95.7%, and 85.3%, respectively ( Table 5 ). The 10-year CSS rates for stage I, II, III, and IV were 100%, 92.9%, 54.7%, and 79.7%, respectively. In TNM-8, the 5-year CSS rates for the four stages were the same as those in TNM-7. The 10-year CSS rates for stage I, II, III, and IV were 100%, 91.7%, 54.7%, and 79.7%, respectively.
In both TNM-7 and TNM-8, most deaths (14 of 18 patients, 77.8%) occurred in patients belonging to the stage IV group, whereas there were three and one deaths in the stage III and stage II groups. According to Cox regression analysis, stage group was not associated with disease-specific mortality (P = 0.125 for TNM-7 and 0.135 for TNM-8). Discriminatory and predictive capacities with respect to disease-specific survival were similar between TNM-7 and TNM-8. The AUCs at 5 and 10 years were 0.786 and 0.679 for TNM-7 and 0.786 and 0.681 for TNM-8, respectively. The PVE and C-index values were 8.8% and 0.746 for TNM-7 and 8.9% and 0.747 for TNM-8, respectively. (Table 6 ). In TNM-7, the 5-year DFS rates for stage I, II, III, and IV were 97.7%, 80.4%, 70.2%, and 52.6%, respectively [ Fig. 2(a) ]. In TNM-8, the 5-year DFS rates for stage I, II, III, and IV were 97.8%, 78.2%, 70.2%, and 52.6%, respectively [ Fig. 2(b) ]. According to Cox regression analysis, DFS was significantly associated with stage group in both staging systems (P , 0.001 for both). Regarding TNM-8, stage I patients had significantly better recurrence outcomes compared stage II patients (HR, 0.158; 95% CI, 0.031 to 0.816; P = 0.028). Compared with stage II patients, stage III patients did not have a statistically significant poorer recurrence outcome (HR, 2.342; 95% CI, 0.757 to 7.248; P = 0.140), whereas stage IV patients did have significantly poorer recurrence outcomes (HR, 4.134; 95% CI, 1.638 to 10.448; P = 0.003). The discriminatory and predictive capacities with respect to DFS were similar between TNM-7 and TNM-8. The AUC at 10 years, PVE, and C-index values were 0.773, 27.1%, and 0.748 for TNM-7 and 0.776, 27.5%, and 0.749 for TNM-8, respectively.
Lastly, upon applying TNM-RPA, the 5-year DFS rates for stage I, II, and III were 90.1%, 75.0%, and 30.5%, respectively [ Fig. 2(c) ]. All patients belonging to stage IV had persistent disease. The AUC at 10 years, PVE, and C-index of TNM-RPA were 0.763, 43.0%, and 0.780, respectively. Comparison of the TNM-8 staging system vs the TNM-RPA staging system A comparison of TNM-8 and TNM-RPA is shown in Table 7 . The proportion of patients belonging to stage I increased from 32.4% (59/182) to 50.6% (92/182) in TNM-RPA compared with TNM-8. Stage I patients classified according to TNM-RPA had larger tumors (1.2 cm vs 0.9 cm; P = 0.041) and more lymph node metastases at diagnosis (19.6% vs 0%; P , 0.001), with a nonsignificant increase in recurrence (10.9% vs 3.4%; P = 0.128) and disease-specific mortality (2.2% vs 0%; P = 0.521) compared with stage I patients classified according to TNM-8. Regarding stage II, the proportion of patients increased from 13.2% (24/182) in TNM-RPA to 30.2% (55/182) in TNM-8. Stage II patients classified according to TNM-RPA had smaller tumors (2.4 cm vs 3.4 cm; P , 0.001), more lymph node metastases at diagnosis (0 vs 83.6%; P , 0.001), a nonsignificant increase in recurrence (43.6% vs 20.8%; P = 0.076), and a similar rate of disease-specific mortality (7.3% vs 8.3%; P = 1.000) compared with stage II patients classified according to TNM-8. The proportion of stage III patients was similar in both staging systems (13.2% and 14.8%), whereas stage III patients classified according to TNM-RPA had larger tumors (3.8 cm vs 1.6 cm; P , 0.001), a significant increase in recurrence (74.1% vs 33.3%; P = 0.005) and a nonsignificant increase in disease-specific mortality (29.6% vs 12.5%; P = 0.182). Because TNM-RPA classified only M1 disease as stage IV, the proportion of stage IV patients in TNM-RPA was notably decreased from 41.2% (75/182) to 4.4% (4/182) compared with TNM-8, along with a significant increase in recurrence (62.7% vs 100%; P = 0.047) and diseasespecific mortality (18.7% vs 75%; P = 0.002).
Discussion
TNM-8 for DTC has been validated in several different cohorts, and almost all studies to date have demonstrated that the revised edition is superior to previous editions with respect to disease-specific survival for patients with DTC (1, 11). However, it remains unclear as to whether the TNM-8 has better prognostic performance for MTC. This study compared the prognostic performance between the TNM-7 and TNM-8 for MTC with respect to cancer-specific mortality. The discriminatory and predictive capacities were similar between TNM-7 and TNM-8, with only 1.1% downstaging of patients from TNM-7 to TNM-8. We also evaluated the same clinical cohort using the alternative prognostic stage groups described in TNM-RPA and found that it exhibited better prognostic performance compared with the AJCC/UICC TNM staging systems. The revised TNM-8 for thyroid cancer comprises several notable changes, including an increased age cutoff from 45 to 55 years, removal of minimal ETE from the definition of T3 disease, and no use of lymph node metastasis location [central neck (N1a) or lateral neck (N1b)] for final staging groupings. After application of these changes, TNM-8 for DTC downstaged a variety of patients from stage IV to stage I and II. Thus, these changes improved the usefulness for predicting survival and guiding appropriate clinical treatment of patients with DTC.
TNM-8 is the first to provide a dedicated staging system for MTC separate from DTC. Indeed, MTC differs from DTC on many points, but previous editions of the AJCC/ UICC TNM staging system did not distinguish between MTC and DTC. Although there are several changes between TNM-7 and TNM-8, the staging system for MTC is still based on the same concepts that were initially developed for DTC. Owing to the rare prevalence and limited available data, developing and evaluating the prognostic ability of staging systems for MTC remain challenging. For this reason, the TNM-8 for MTC requires further amendment. TNM-8 for MTC uses the same T, N, and M category definitions as TNM-8 for DTC. In addition, there has not been a change in TNM-8 for MTC with respect to final prognostic stage groups; these are the same as in TNM-7. On the basis of accumulating evidence, TNM-8 for DTC reclassified a significantly higher proportion of patients from stage III-IV to stage I-II. Whereas a variety of patients with DTC were downstaged after application of the revised TNM-8, TNM-8 for MTC still upstaged many patients.
Boostrom et al. (5) reported that the 5-year CSS of MTC is similar between stages III and IVa (96% and 94%, respectively) according to the sixth edition of the AJCC/UICC TNM staging system, whereas stage IVb and IVc patients exhibit poorer outcomes (50% and 56%, respectively). In our study, TNM-8 for MTC distributed a significant number of patients into stage IV, which resulted in better long-term survival better for stage IV patients compared with stage III patients. Patients with heterogeneous prognoses were grouped together in stage IV, which could potentially lead to overtreatment. On the basis of this possibility, TNM-RPA downstaged a significant number of patients and assigned more patients to an earlier stage. As a result, applying TNM-RPA had a better prognostic performance compared with TNM-8, but too many patients were assigned to stage I. An analysis of Surveillance, Epidemiology, and End Results data showed that more than half (54.2%, 1797/3315) of patients have stage I disease according to the TNM-RPA criteria and only 5.0% (165/3315) of patients have stage IV disease (6). Consistently, 50.5% (92/182) and 4.4% (8/182) of the patients in our study had stage I and stage IV disease according to the TNM-RPA classification, respectively. Contrary to the Will Rogers phenomenon or staging migration (12) , TNM-RPA reclassified more patients as having earlier disease stage, which may worsen survival outcomes for all stage groups but improve the prognostic performance of the staging system. Thus, although it may be possible to more accurately select patients with a poor prognosis, there is a potential for undertreatment with TNM-RPA due to an inability to distinguish between the prognoses of patients with early-stage disease. A few reports have suggested that current staging systems are inappropriate (5, 13) . Some authors have also tried to develop tools to more accurately predict outcomes. Yang et al. (14) and Ho et al. (15) suggested that including the first postoperative calcitonin measurement with current staging system may better predict oncologic outcomes of patients with MTC. In addition, whether the disease is hereditary or sporadic is one of the most important factors related to MTC mortality (16) (17) (18) . However, there is currently no consensus on how these factors, including tumor markers and genetic mutations, could be integrated into MTC staging systems. Nevertheless, an appropriate and comprehensive analysis might lead to the incorporation of some of these factors as important staging system components (e.g., age in DTC staging and human papillomavirus in oropharyngeal cancer staging) (19, 20) .
The main limitations of this study were its retrospective study design and the fact that it was conducted in a single center. However, a study using the National Cancer Database and the Surveillance, Epidemiology, and End Results data set showed that the 5-year CSS were 100% in stage I, 99% in stage II, 97% in stage III, and 82% in stage IV, which is consistent with our findings (6) . In addition, our study had limited prognostic power by the small number of patients included. It was practically difficult to expand the study cohort because of the rare prevalence of MTC, as it was in the previous studies (21, 22) . Further multicenter cohort studies with sufficient statistical power are required to assess the utility of current cancer staging systems. The strengths of this study were its long-term follow-up period and adjudication for the occurrence of oncologic outcomes based on detailed clinical data. We also included essential intraoperative findings regarding the extent of ETE, which are generally not included in administrative and registry data sources. Thus, our study may have valuable implications with respect to providing data on the real-world prognostic ability of TNM-8 and also suggests potential areas of improvement to be made by implementation of the alternative prognostic stage groups of TNM-RPA.
In conclusion, the predictive performance of the revised TNM-8 in patients with MTC has not changed despite the modification from the TNM-7. The proposed changes in TNM-RPA were statistically valid and may represent a more reproducible system that better estimates cancer-specific survival for individual patients. However, TNM-RPA appears to have limited value with respect to discriminating among patients with early-stage MTC. Thus, further studies are needed to modify current MTC staging systems to achieve appropriate prognostic prediction and treatment decisions.
